392 related articles for article (PubMed ID: 10841436)
1. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists.
Gilbert JD; Cahill SA; McCartney DG; Lukas A; Gross GJ
Can J Physiol Pharmacol; 2000 May; 78(5):407-14. PubMed ID: 10841436
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.
Hey JA; del Prado M; Sherwood J; Kreutner W; Egan RW
Arzneimittelforschung; 1996 Feb; 46(2):153-8. PubMed ID: 8720304
[TBL] [Abstract][Full Text] [Related]
3. [The effect of second generation histamine antagonists on the heart].
Grzelewska-Rzymowska I; Pietrzkowicz M; Górska M
Pneumonol Alergol Pol; 2001; 69(3-4):217-26. PubMed ID: 11575008
[TBL] [Abstract][Full Text] [Related]
4. Second-generation antihistamines: the risk of ventricular arrhythmias.
DuBuske LM
Clin Ther; 1999 Feb; 21(2):281-95. PubMed ID: 10211532
[TBL] [Abstract][Full Text] [Related]
5. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
[TBL] [Abstract][Full Text] [Related]
6. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole.
Vorperian VR; Zhou Z; Mohammad S; Hoon TJ; Studenik C; January CT
J Am Coll Cardiol; 1996 Nov; 28(6):1556-61. PubMed ID: 8917271
[TBL] [Abstract][Full Text] [Related]
7. Cardiac actions of antihistamines.
Woosley RL
Annu Rev Pharmacol Toxicol; 1996; 36():233-52. PubMed ID: 8725389
[TBL] [Abstract][Full Text] [Related]
8. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
9. [Torsades de pointes caused by cetirizine overdose].
Renard S; Ostorero M; Yvorra S; Zerrouk Z; Bargas E; Bertocchio P; Pracchia S; Ebagosti A
Arch Mal Coeur Vaiss; 2005 Feb; 98(2):157-61. PubMed ID: 15787309
[TBL] [Abstract][Full Text] [Related]
10. Does the sedative agent, JM-1232(-) cause QT prolongation with subsequent torsades de pointes?
Kato R; Watanabe R; Miki H; Ijiri Y; Hayashi T; Tanaka K
Life Sci; 2009 Nov; 85(21-22):737-41. PubMed ID: 19833140
[TBL] [Abstract][Full Text] [Related]
11. Potential cardiac toxicity of H1-antihistamines.
Yap YG; Camm AJ
Clin Allergy Immunol; 2002; 17():389-419. PubMed ID: 12113224
[TBL] [Abstract][Full Text] [Related]
12. Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia.
Fabritz L; Kirchhof P; Franz MR; Eckardt L; Mönnig G; Milberg P; Breithardt G; Haverkamp W
Basic Res Cardiol; 2003 Feb; 98(1):25-32. PubMed ID: 12494266
[TBL] [Abstract][Full Text] [Related]
13. Experimental study on the mechanism of sex difference in the risk of torsade de pointes.
Ruan YF; Liu N; Zhou Q; Li Y; Wang L
Chin Med J (Engl); 2004 Apr; 117(4):538-41. PubMed ID: 15109445
[TBL] [Abstract][Full Text] [Related]
14. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
[TBL] [Abstract][Full Text] [Related]
15. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
[TBL] [Abstract][Full Text] [Related]
16. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?
Cavero I; Mestre M; Guillon JM; Heuillet E; Roach AG
Drug Saf; 1999; 21 Suppl 1():19-31; discussion 81-7. PubMed ID: 10597865
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance.
Adamantidis MM; Lacroix DL; Caron JF; Dupuis BA
J Cardiovasc Pharmacol; 1995 Aug; 26(2):319-27. PubMed ID: 7475058
[TBL] [Abstract][Full Text] [Related]
18. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3.
Milberg P; Reinsch N; Osada N; Wasmer K; Mönnig G; Stypmann J; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Jul; 100(4):365-71. PubMed ID: 15944809
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular toxicity of antihistamines.
Smith SJ
Otolaryngol Head Neck Surg; 1994 Sep; 111(3 Pt 2):348-54. PubMed ID: 7916150
[TBL] [Abstract][Full Text] [Related]
20. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
Di Diego JM; Belardinelli L; Antzelevitch C
Circulation; 2003 Aug; 108(8):1027-33. PubMed ID: 12912819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
